| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net income | 131,676 | 79,346 | 28,380 | 19,153 |
| Depreciation and amortization | 40,284 | 25,883 | 12,705 | 27,893 |
| Amortization of deferred financing fees | 2,361 | 1,574 | 787 | 2,333 |
| Stock-based compensation | 38,322 | 25,806 | 12,202 | 103,240 |
| Loss on investment in partnership | -800 | -312 | - | -3,572 |
| Gain on insurance subsidiary deposits and investments | 4,004 | 2,864 | 1,652 | 2,200 |
| Deferred taxes | -31,537 | -17,029 | -19,580 | -45,250 |
| Noncash lease expense | 37,071 | 25,140 | 12,703 | 22,973 |
| Other noncash operating activities, net | 110 | 29 | 298 | 843 |
| Accounts receivable, net | -13,495 | -3,648 | 38,901 | 26,835 |
| Other receivables | -8,318 | -23,101 | -13,721 | -2,934 |
| Prepaid expenses and other current assets | 6,963 | 23,836 | -11,800 | 5,112 |
| Other assets | 7,684 | 14,526 | 3,833 | 14,879 |
| Escrow funds | -704 | -1,716 | -3,312 | 7,935 |
| Operating lease liabilities | -1,333 | -1,005 | 64 | -20,913 |
| Accounts payable | 27,067 | -4,740 | 20,606 | 10,339 |
| Accrued payroll and benefits | 106,361 | 43,959 | 61,446 | 61,651 |
| Accrued self-insurance liabilities | 57,449 | 50,143 | 21,224 | 48,593 |
| Refund liability | 35,338 | 27,800 | 16,359 | 83,987 |
| Other accrued expenses | 37,300 | 105,875 | 22,280 | 37,294 |
| Other liabilities | -77,521 | -147,514 | -23,677 | 1,070 |
| Net cash provided by operating activities | 407,614 | 202,818 | 150,244 | 302,751 |
| Investment in partnerships | 0 | 0 | 0 | 30,426 |
| Non-operating distributions from investment in partnership | 4,176 | 2,822 | 1,301 | 2,216 |
| Purchase of available-for-sale securities | 15,162 | 15,111 | 0 | 45,000 |
| Acquisition of facilities | 80,594 | 243 | 0 | 224,761 |
| Purchase of property and equipment | 54,299 | 36,289 | 17,717 | 41,874 |
| Proceeds from the sale of assets | 0 | - | - | 1,500 |
| Net cash used in investing activities | -145,879 | -48,821 | -16,416 | -338,345 |
| Borrowing on line of credit, net of deferred financing fees | 0 | 0 | 0 | 402,000 |
| Payments on line of credit | 42,000 | 0 | 0 | 922,000 |
| Borrowings of long-term debt, net of deferred financing fees | 0 | 0 | 0 | 70,116 |
| Payments on long-term debt | 12,748 | 9,022 | 4,065 | 13,839 |
| Noncontrolling interest distribution | 378 | 220 | - | - |
| Contributions from noncontrolling interest | 0 | 0 | - | 502 |
| Dividends on common stock | 0 | 0 | 0 | 33,721 |
| Proceeds from initial public offering, net of issuance costs | 0 | 0 | - | 414,157 |
| Proceeds from common stock offering, net of issuance costs | 0 | - | - | 95,285 |
| Taxes paid related to net share settlement of stock-based compensation awards | 8,395 | 7,955 | - | 33,598 |
| Net cash used in financing activities | -63,521 | -17,197 | -4,065 | -21,098 |
| Net change in cash | 198,214 | 136,800 | 129,763 | -56,692 |
| Cash and cash equivalents at beginning of period | 160,842 | 160,842 | 160,842 | 118,704 |
| Cash and cash equivalents at end of period | 359,056 | 297,642 | 290,605 | 62,012 |
PACS Group, Inc. (PACS)
PACS Group, Inc. (PACS)